JP2005510478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510478A5 JP2005510478A5 JP2003533966A JP2003533966A JP2005510478A5 JP 2005510478 A5 JP2005510478 A5 JP 2005510478A5 JP 2003533966 A JP2003533966 A JP 2003533966A JP 2003533966 A JP2003533966 A JP 2003533966A JP 2005510478 A5 JP2005510478 A5 JP 2005510478A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- use according
- antigen
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims 10
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- -1 1-Iminoethylamino Chemical group 0.000 claims 4
- RODUKNYOEVZQPR-UHFFFAOYSA-N N-[3-(aminomethyl)benzyl]acetamidine Chemical compound CC(=N)NCC1=CC=CC(CN)=C1 RODUKNYOEVZQPR-UHFFFAOYSA-N 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- DDGULJZAQPDKQZ-LURJTMIESA-N (2r)-2-amino-3-[2-(1-aminoethylideneamino)ethylsulfonyl]propanoic acid Chemical compound CC(=N)NCCS(=O)(=O)C[C@H](N)C(O)=O DDGULJZAQPDKQZ-LURJTMIESA-N 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 2
- 239000010931 gold Substances 0.000 claims 2
- 229910052737 gold Inorganic materials 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001965 increasing effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124022.5A GB0124022D0 (en) | 2001-10-05 | 2001-10-05 | Novel compounds |
| PCT/GB2002/004365 WO2003030935A2 (en) | 2001-10-05 | 2002-09-26 | Adjuvants for nucleic acid vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510478A JP2005510478A (ja) | 2005-04-21 |
| JP2005510478A5 true JP2005510478A5 (https=) | 2006-01-05 |
Family
ID=9923350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003533966A Pending JP2005510478A (ja) | 2001-10-05 | 2002-09-26 | ワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050054726A1 (https=) |
| EP (1) | EP1432440A2 (https=) |
| JP (1) | JP2005510478A (https=) |
| AU (1) | AU2002327959A1 (https=) |
| CA (1) | CA2462582A1 (https=) |
| GB (1) | GB0124022D0 (https=) |
| WO (1) | WO2003030935A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002951692A0 (en) * | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
| US7796173B2 (en) * | 2003-08-13 | 2010-09-14 | Lettvin Jonathan D | Imaging system |
| US20120056006A1 (en) * | 2010-09-03 | 2012-03-08 | David Bendah | Global warming letter |
| AU2015323944B2 (en) * | 2014-10-01 | 2018-11-29 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-21 as an adjuvant |
| GB201512635D0 (en) * | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
| US20260083844A1 (en) * | 2022-09-15 | 2026-03-26 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Downregulating inos to increase car-t killing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060008448A1 (en) * | 1996-06-11 | 2006-01-12 | Minzhen Xu | Inhibition of li expression in mammalian cells |
| US6375944B1 (en) * | 1998-09-25 | 2002-04-23 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 |
-
2001
- 2001-10-05 GB GBGB0124022.5A patent/GB0124022D0/en not_active Ceased
-
2002
- 2002-09-26 US US10/491,843 patent/US20050054726A1/en not_active Abandoned
- 2002-09-26 CA CA002462582A patent/CA2462582A1/en not_active Abandoned
- 2002-09-26 AU AU2002327959A patent/AU2002327959A1/en not_active Abandoned
- 2002-09-26 WO PCT/GB2002/004365 patent/WO2003030935A2/en not_active Ceased
- 2002-09-26 EP EP02762572A patent/EP1432440A2/en not_active Withdrawn
- 2002-09-26 JP JP2003533966A patent/JP2005510478A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220347307A1 (en) | Messenger rna vaccines and uses thereof | |
| ES2572811T3 (es) | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos | |
| JP2020202826A (ja) | コードされている病原体抗原の発現を増加させるための、ヒストンステムループとポリ（ａ）配列又はポリアデニル化シグナルとを含むか又はコードしている核酸 | |
| US20200046830A1 (en) | Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines | |
| JP2009530277A5 (https=) | ||
| JP2014520120A5 (https=) | ||
| JP2010017190A (ja) | アジュバントとしてのコレラホロトキシンの突然変異形 | |
| JPWO2020219941A5 (https=) | ||
| HRP20140102T1 (hr) | Cjepivo za prevenciju relapsa raka dojke | |
| JP2024036364A (ja) | Ｉ型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物 | |
| JP2005510478A5 (https=) | ||
| FR2832410A1 (fr) | Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene | |
| JP2002513811A (ja) | 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のｄｎａまたは裸のｒｎａの導入 | |
| WO2024131833A1 (en) | Mrna-based hpv+ cancer vaccines, and uses thereof | |
| EP2314311B1 (fr) | Péptides et leur application en thérapeutique | |
| Kaur et al. | Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
| RU2002128351A (ru) | Применение mia в иммунотерапии | |
| Riedl et al. | Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines | |
| JPWO2021094562A5 (https=) | ||
| WO1995028958A1 (en) | Induction of cytotoxic t lymphocytes (ctl) using antigenic peptides and a suitable adjuvant | |
| EP2638062B1 (en) | New adjuvant | |
| AU2012300181B2 (en) | Peptides for use in the treatment of IL-1 related diseases and conditions | |
| US20140356391A1 (en) | Amino acid sequences for clinical remission of psoriasis and related diseases. | |
| Karami et al. | CpG motif as an adjuvant in immunization of a recombinant plasmid encoding hepatitis C virus core protein |